MedTrace Logo

EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction

NCT01490489 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2025-11-18

No results posted yet for this study

Summary

The purpose of this study is to assess the potential prognostic value of seric concentrations of EG-VEGF for Pre-eclampsia and/or intrauterine growth restriction and will allow checking whether plasma levels of EG-VEGF at 14-18 weeks of gestation could be proposed as prognostic marker for preeclampsia.

Conditions

  • Pre-eclampsia
  • Intra-uterine Growth Retardation

Interventions

OTHER

blood sample and doppler Ultrasound of uterine arteries

* 36 ml of blood samples (serum and plasma) will be collected * After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Principal Investigators

  • Pascale Hoffmann, MD/PHD · University Hospital, Grenoble

  • Nadia ALFAIDI, PHD · inserm U878

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-11
Primary Completion
2015-03-31
Completion
2015-03-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01490489 on ClinicalTrials.gov